EUVIMEDEUVIMED entdecken
Open Access

A health facility-based assessment of the ancillary benefit for prevention of anaemia at term of intermittent preventive therapy with sulfadoxine-pyrimethamine in pregnancy

Brainard A Asare, Grace Asare

Ghana Medical Journal · 2025

DOI: 10.4314/gmj.v58i4.4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Ghana Medical Journal, 2025. Verfasst von Brainard A Asare und 1 weiteren Autor:innen. Beteiligte Einrichtung: Ghana Health Service, Kwaebibirem Municipal Health Directorate, Kade, Eastern Region, Ghana. Hauptthemen laut MEDLINE: Pyrimethamine, Sulfadoxine, Antimalarials, Anemia. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study aims to evaluate the ancillary benefit of intermittent preventive therapy with sulfadoxine-pyrimethamine ( IPTp-SP) in preventing maternal anaemia (MA) among parturient women differentially exposed to the regimen.

Design

A health facility-based retrospective analytical cross-sectional study.Settings: The study was conducted at the Kade Government Hospital’s maternity/labor suit.

Participants

Data from 2,545 parturient women were abstracted from birth registers.Statistical analysis: Baseline characteristics were described, and stratified analyses assessed their impacts. Differences in mean mHgbc based on IPTp-SP exposure were determined using one-way ANOVA. An unpaired two-sample t-test evaluated the significance of inter-dose group differences. The bivariable analysis examined crude and adjusted risks of anaemia with differential IPTp-SP exposure.Main outcome measure: The main outcome measure was the level of mHgbc with varying IPTp-SP exposure.

Results

The overall mean exposure to IPTp-SP was 2.35 (±2.35) doses. Of the women, 5.9% had ‘nil’ exposure, with a mean mHgbc of 9.71 g/dL (±1.6). Among the 75.9% who received 1-3 doses, the mean mHgbc was 10.39 g/dL (±1.3). For the 18.2% who received ≥4 doses, the mean mHgbc was 10.77 g/dL (±1.4). The mHgbc notably rose as the mean doses of IPTp-SP increased. The crude odds ratios (COR) were 1.96 (95% CI: 0.99-3.89, p = 0.06) for ‘nil’ exposure, 1.28 (95% CI: 0.92-1.78, p = 0.16) for 1-3 doses, and 0.59 (95% CI: 0.41-0.84, p = 0.002) for ≥4 doses.

Conclusion

The consistent linear increase in mean mHgbc with higher IPTp-SP doses remains clinically crucial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrimethamineSulfadoxineAntimalarialsAnemiaPregnancy Complications, HematologicHumansFemalePregnancyDrug CombinationsRetrospective StudiesCross-Sectional StudiesAdultYoung AdultPregnancy Complications, ParasiticMalaria

Stichwörter der Autor:innen

Intermittentanaemiabenefitmaternalpregnancypreventivetherapy

Substanzen

PyrimethamineSulfadoxinefanasil, pyrimethamine drug combinationDrug CombinationsAntimalarials

Autor:innen und Institutionen

  • Ghana Health Service, Kwaebibirem Municipal Health Directorate, Kade, Eastern Region, Ghana.
  • Ghana Health Service, Kade Government Hospital, Eastern Region, Ghana.

Zitieren

APA

Asare, B. A., & Asare, G. (2025). A health facility-based assessment of the ancillary benefit for prevention of anaemia at term of intermittent preventive therapy with sulfadoxine-pyrimethamine in pregnancy. Ghana Medical Journal. https://doi.org/10.4314/gmj.v58i4.4

Vancouver

Asare BA, Asare G. A health facility-based assessment of the ancillary benefit for prevention of anaemia at term of intermittent preventive therapy with sulfadoxine-pyrimethamine in pregnancy. Ghana Medical Journal. 2025. doi:10.4314/gmj.v58i4.4

BibTeX
@article{Asare2025,
  author = {Asare, Brainard A and Asare, Grace},
  title = {A health facility-based assessment of the ancillary benefit for prevention of anaemia at term of intermittent preventive therapy with sulfadoxine-pyrimethamine in pregnancy},
  journal = {Ghana Medical Journal},
  year = {2025},
  doi = {10.4314/gmj.v58i4.4}
}
Kostenlos starten →